The specter of generic competition has long loomed around copyright’s blockbuster drug, Sildenafil, triggering questions about the future of related drug holdings. While first periods saw substantial returns, the exclusivity expiration has created the door for less expensive substitutes, likely diminishing profitability and creating a genuine haz